Atlas Trials

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

Clinical trial NCT05076695 · UNKNOWN

Trial details

NCT number
NCT05076695
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Estrogen Receptor-positive Breast CancerHER2-positive Breast Cancer
Start date
2021-10-15
Primary completion
2023-10-15
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.